

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1 Name and Address of Company

HYTN Innovations Inc. (the “Company”)
12 East 4th Avenue
Vancouver, BC
Canada V5T 1E8

Item 2 Date of Material Change

June 27, 2024

Item 3 News Release

The Company disseminated a news release announcing the material change described herein through the news dissemination service of Globe Newswire on June 27, 2024, and a copy was subsequently filed on SEDAR+.

Item 4 Summary of Material Change

The Company announced that it has been granted a Drug Establishment License (DEL) by Health Canada.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

The Company announced that it has been granted a Drug Establishment License (DEL) by Health Canada. This license allows HYTN to engage in the GMP fabrication, packaging, and labeling of non-sterile pharmaceuticals containing both cannabis and psilocybin.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

For further information, please contact Elliot McKerr, Chief Executive Officer of 866-590-9289 or via email to investments@hytn.life.

Item 9 Date of Report

June 28, 2024